GSK (NYSE:GSK) Stock Rating Lowered by Deutsche Bank Aktiengesellschaft

GSK (NYSE:GSK) was downgraded by Deutsche Bank Aktiengesellschaft from a “buy” rating to a “hold” rating in a research note issued to investors on Friday, Marketbeat.com reports.

Several other research firms have also weighed in on GSK. Argus upgraded GSK to a “strong-buy” rating in a report on Wednesday, August 7th. Guggenheim cut shares of GSK from a “buy” rating to a “neutral” rating in a research report on Thursday, October 31st. Jefferies Financial Group downgraded GSK from a “buy” rating to a “hold” rating and cut their price objective for the company from $53.00 to $39.50 in a report on Tuesday. Finally, Barclays raised GSK to a “hold” rating in a research report on Tuesday, August 27th. Seven research analysts have rated the stock with a hold rating and three have issued a strong buy rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $43.25.

GSK Price Performance

GSK stock opened at $34.38 on Friday. The company has a current ratio of 0.81, a quick ratio of 0.53 and a debt-to-equity ratio of 0.98. The firm has a market capitalization of $71.24 billion, a P/E ratio of 22.32, a PEG ratio of 1.35 and a beta of 0.66. The business has a 50-day moving average of $39.46 and a 200-day moving average of $40.80. GSK has a 1 year low of $34.29 and a 1 year high of $45.92.

Insider Buying and Selling

In related news, major shareholder Plc Gsk bought 2,791,930 shares of the business’s stock in a transaction on Friday, September 27th. The shares were purchased at an average price of $8.00 per share, for a total transaction of $22,335,440.00. Following the completion of the transaction, the insider now directly owns 16,775,691 shares of the company’s stock, valued at approximately $134,205,528. This represents a 19.97 % increase in their position. The acquisition was disclosed in a document filed with the SEC, which is available through this link. 10.00% of the stock is owned by company insiders.

Institutional Investors Weigh In On GSK

Several hedge funds have recently modified their holdings of the company. SG Americas Securities LLC increased its stake in shares of GSK by 448.7% in the first quarter. SG Americas Securities LLC now owns 17,690 shares of the pharmaceutical company’s stock valued at $758,000 after buying an additional 14,466 shares during the period. Kingsview Wealth Management LLC raised its position in shares of GSK by 3.4% during the first quarter. Kingsview Wealth Management LLC now owns 17,276 shares of the pharmaceutical company’s stock worth $741,000 after purchasing an additional 563 shares during the period. Blair William & Co. IL increased its position in shares of GSK by 14.9% during the first quarter. Blair William & Co. IL now owns 23,493 shares of the pharmaceutical company’s stock worth $1,007,000 after acquiring an additional 3,044 shares in the last quarter. Nwam LLC increased its holdings in GSK by 126.4% during the 1st quarter. Nwam LLC now owns 16,080 shares of the pharmaceutical company’s stock worth $710,000 after purchasing an additional 8,976 shares in the last quarter. Finally, TIAA Trust National Association bought a new position in GSK during the 1st quarter valued at $302,000. Institutional investors and hedge funds own 15.74% of the company’s stock.

About GSK

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.